Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06634420 · ClinicalTrials.gov registry record · Phase 3
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
A Phase 3 study of Hereditary Angioedema, sponsored by Intellia Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT06634420 is a Phase 3 study of Hereditary Angioedema that is active but no longer recruiting, run by Intellia Therapeutics. The registered enrollment target is 60 participants, below the 72-participant average among 14 other Hereditary Angioedema trials with a reported enrollment target (17% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT06634420, a Phase 3 study of Hereditary Angioedema, is active but no longer recruiting, sponsored by Intellia Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase 3 study aims to evaluate the efficacy and safety of NTLA-2002 compared to placebo in participants with HAE.
Conditions Studied
Interventions
- BIOLOGICAL NTLA-2002
- BIOLOGICAL Normal Saline IV Administration
Study Locations (20)
California
- University of California, San Diego (UCSD) - San Diego
- Raffi Tachdjian MD, Inc - Santa Monica
- Allergy & Asthma Clinical Research - Walnut Creek
Colorado
- IMMUNOe International Research Centers - Centennial
- Asthma & Allergy Associates - Colorado Springs
New York
- NYU Langone Health - Long Island - Mineola
- Icahn School of Medicine at Mount Sinai - New York
Victoria
- The Alfred Hospital - Melbourne
- Royal Melbourne Hospital - Parkville
Arizona
- Medical Research of Arizona - Scottsdale
Florida
- University of South Florida - Tampa
Massachusetts
- Massachusetts General Hospital - Boston
Missouri
- Washington University in St. Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-01-15 |
| Est. Completion | 2027-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06634420
The ClinicalTrials.gov registry entry for NCT06634420 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 72-participant average among 14 other Hereditary Angioedema trials with a reported enrollment target (17% lower). The listed sponsor is Intellia Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hereditary Angioedema appearing as the primary indexed condition, and to 2 interventions - of which NTLA-2002 is the first listed.
NCT06634420 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Colorado, New York.
Frequently Asked Questions
What is clinical trial NCT06634420 about?
NCT06634420 is a clinical study titled "HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)". This Phase 3 study aims to evaluate the efficacy and safety of NTLA-2002 compared to placebo in participants with HAE.
What is the current status of trial NCT06634420?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2025-01-15. Estimated completion is 2027-09.
What conditions does trial NCT06634420 study?
This clinical trial studies the following conditions: Hereditary Angioedema.
What interventions are being tested in trial NCT06634420?
The interventions under investigation include: NTLA-2002 (BIOLOGICAL), Normal Saline IV Administration (BIOLOGICAL).
Who is sponsoring clinical trial NCT06634420?
This trial is sponsored by Intellia Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06634420 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Angioedema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
RECRUITING · Phase 3
-
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
ACTIVE NOT RECRUITING · Phase 3
-
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
ACTIVE NOT RECRUITING · Phase 3
-
Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks
COMPLETED · Phase 3
-
OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.